Cellinta Ltd.

https://www.cellinta.com

LinkedIn: https://linkedin.com/company/cellinta-limited

Cellinta is a biotechnology company focused on developing highly selective gene therapies for cancer. Cellinta’s first-in-class gene therapies harnesses master regulators governing cell identity to deliver therapeutic agents selectively to cancer stem cells. The Company's platform leverages the expertise and recent discoveries across stem cell biology, synthetic biology and cancer genomics of its renowned founding scientist, Professor Steve Pollard from the University of Edinburgh, UK. This builds upon the advancements of viral vectors as a clinically validated and scalable platform to rapidly develop new treatments for patients. *

	Start	2019-08-16 established (s-off)
	Predecessor	University of Edinburgh
	Industry	gene therapy
	Person	Bekkali, Soraya (Cellinta 202007– CEO before Gyroscope Therapeutics + Lysogene + Orphan Europe + Sanofi)

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	71 Kingsway
	City	WC2B 6ST London
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Cellinta Ltd.. (9/15/20). "Press Release: Launch of Cellinta and Appointment of Dr Soraya Bekkali as CEO". London.

		Record changed: 2023-07-10

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Cellinta Ltd.

[1] Cellinta Ltd.. (9/15/20). "Press Release: Launch of Cellinta and Appointment of Dr Soraya Bekkali as CEO". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]